Novel and recurrent PITX3 mutations in Belgian families with autosomal dominant congenital cataract and anterior segment dysgenesis have similar phenotypic and functional characteristics by Verdin, Hannah et al.
  
 
 
 
 
 
Citation VERDIN H., SOROKINA E.A., MEIRE F., CASTEELS I., DE RAVEL 
T., SEMINA E.V., DE BAERE E. (2014), 
Novel and recurrent PITX3 mutations in Belgian families with 
autosomal dominant congenital cataract and anterior segment 
dysgenesis have similar phenotypic and functional characteristics 
Orphanet J Rare Dis., 9(1), 26,  
Archived version Final publisher’s version / pdf 
Published version http://www.ojrd.com/content/9/1/26 
doi:10.1186/1750-1172-9-26 
Journal homepage http://www.ojrd.com/ 
Author contact  
Klik hier als u tekst wilt invoeren. 
IR https://lirias.kuleuven.be/handle/123456789/442235 
 
(article begins on next page) 
Verdin et al. Orphanet Journal of Rare Diseases 2014, 9:26
http://www.ojrd.com/content/9/1/26RESEARCH Open AccessNovel and recurrent PITX3 mutations in Belgian
families with autosomal dominant congenital
cataract and anterior segment dysgenesis have
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Background: Congenital cataracts are clinically and genetically heterogeneous with more than 45 known loci and
38 identified genes. They can occur as isolated defects or in association with anterior segment developmental
anomalies. One of the disease genes for congenital cataract with or without anterior segment dysgenesis (ASD) is
PITX3, encoding a transcription factor with a crucial role in lens and anterior segment development. Only five
unique PITX3 mutations have been described, of which the 17-bp duplication c.640_656dup, p.(Gly220Profs*95), is
the most common one and the only one known to cause cataract with ASD. The aim of this study was to perform
a genetic study of the PITX3 gene in five probands with autosomal dominant congenital cataract (ADCC) and ASD,
to compare their clinical presentations to previously reported PITX3-associated phenotypes and to functionally
evaluate the PITX3 mutations found.
Methods: Sanger sequencing of the coding region and targeted exons of PITX3 was performed in probands and
family members respectively. Transactivation, DNA-binding and subcellular localization assays were performed
for the PITX3 mutations found. Ophthalmological examinations included visual acuity measurement, slit-lamp
biomicroscopy, tonometry and fundoscopy.
Results: In four Belgian families with ADCC and ASD the recurrent 17-bp duplication c.640_656dup, p.(Gly220-
Profs*95), was found in a heterozygous state. A novel PITX3 mutation c.573del, p.(Ser192Alafs*117), was identified in
heterozygous state in a Belgo-Romanian family with a similar phenotype. Functional assays showed that this novel
mutation retains its nuclear localization but results in decreased DNA-binding and transactivation activity, similar to
the recurrent duplication.
Conclusions: Our study identified a second PITX3 mutation leading to congenital cataract with ASD. The similarity
in phenotypic expression was substantiated by our in vitro functional studies which demonstrated comparable
molecular consequences for the novel p.(Ser192Alafs*117) and the recurrent p.(Gly220Profs*95) mutations.* Correspondence: elfride.debaere@ugent.be
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Cataract is defined as opacity or cloudiness of the crystal-
line lens. It is the primary cause of blindness worldwide
and is classified into different types based on the age of
onset. Congenital cataract manifests in the first year of life;
the estimated incidence of congenital cataract is 72 per
100,000 children in developed countries with a higher in-
cidence in less-developed countries. Congenital cataract is
clinically and genetically heterogeneous with about 45 loci
known and 38 genes identified. Mutations in genes
encoding proteins important in the development and
maintenance of the structural integrity of the lens such
as crystallins, connexins and aquaporins [1,2] are typically
associated with isolated congenital cataracts while muta-
tions in the transcription factor genes PAX6 [3], FOXE3
[4], EYA1 [5], MAF [6], and PITX3 [7] have been de-
scribed in congenital cataract with anterior segment dys-
genesis (ASD). ASD is an umbrella term for the spectrum
of developmental disorders affecting the structures of the
anterior segment of the eye. The ocular anomalies typic-
ally include corneal opacity, adhesions between the iris
and cornea or lens and cornea, iris hypoplasia, corectopia
or polycoria, and malformation of the irido-corneal angle
drainage structures [8].
PITX3 was isolated as the third gene of the PITX
homeobox-containing transcription factor gene family
[9,10], along with PITX1 [11,12] and PITX2 [13]. The
PITX protein family is a subfamily of the paired-like class
of the homeobox-containing proteins, which play a crucial
role in the development of different organisms including
mammals. Like the other members of this family, PITX3
contains a characteristic and strongly conserved homeo-
domain required for DNA binding. The conserved 14-
amino acid OAR motif, named after the homeodomain
proteins otp, aristaless, and rax [14], is located down-
stream of this homeodomain, and may function in the tar-
get specificity and transactivation of the homeodomain
protein [13,14]. Interestingly, Pitx3 mapped to the apha-
kia (ak) locus [9], a recessive mutation resulting in bilat-
eral microphthalmia with lens aplasia originally described
by Varnum and Stevens in 1968. The lens develops nor-
mally in ak mice until an arrest occurs around embryonic
days 10.5–11 [15] corresponding to the moment of initial
expression of Pitx3 in the lens [7,9]. Consequently, Pitx3
was the top candidate for the ak phenotype but no mu-
tation was found in the coding region of Pitx3 [9]. Two
different deletions in the promoter region of Pitx3 were
later found to explain the ak phenotype [16,17]. Before
this finding, the first human PITX3 mutations had
already been identified in two families with autosomal
dominant congenital cataract (ADCC). A 17-bp duplica-
tion c.640_656dup, p.(Gly220Profs*95), was found in a
family with ADCC and ASD while a missense mutation
c.38G > A, (Ser13Asn), was identified in a second family[7]. Since the original gene identification study, there
have been only a few additional mutations identified,
bringing the total number of unique PITX3 mutations
found in ADCC with or without ASD to five mutations
in 13 different families [7,18-26]. Two of these muta-
tions are recurrent, the most common one being the 17-
bp duplication p.(Gly220Profs*95) which was reported
in eight of the 13 families [7,18-21,23,24]. The other
recurrent mutation is a 1-bp deletion at position 650, p.
(Gly217Alafs*92), found in two families [18,22]. Thus far,
only the 17-bp duplication has been associated with ASD;
all other mutations are reported with isolated cataract. Of
particular note, homozygous PITX3 mutations were also
described in two consanguineous pedigrees [22,25].
The aim of this study was to analyze the PITX3 gene in
five Belgian families with ADCC and ASD. We identified
the recurrent 17-bp duplication c.640_656dup, p.(Gly220-
Profs*95), in four of these families, and a novel PITX3mu-
tation c.573del, p.(Ser192Alafs*117), in a fifth family. In
vitro functional assays were performed for both mutations,
showing similar functional characteristics. In conclusion,
the similar ADCC and ASD phenotypes resulting from
both mutations could be explained by our in vitro func-
tional studies.Methods
Patients
The consenting families enrolled in this study were re-
ferred for clinical genetic testing of ADCC and ASD.
Prior to this study, they underwent mutation screening
of the coding regions of the FOXC1 and PITX2 genes by
Sanger sequencing and multiplex-ligation dependent
probe amplification (MLPA), as described [27]. A total
of four Belgian families and one Belgo-Romanian family
were investigated for coding mutations in the PITX3
gene. Ophthalmological examinations included visual
acuity measurements, slit-lamp biomicroscopy, tonome-
try and fundoscopy. The study was performed in ac-
cordance with the Declaration of Helsinki.Molecular genetic study of PITX3
The coding region of PITX3 was screened using PCR
amplification and subsequent Sanger sequencing. Primer
pairs for the coding exons and PCR conditions can be
found in Additional file 1. Sequencing was performed with
the BigDye Terminator v3.1 Cycle Sequencing Kit on an
ABI 3730XL genetic Analyzer, according to the manufac-
turer’s instructions (Applied Biosystems, Carlsbad, CA).
Mutation nomenclature is based on reference transcript
NM_005029.3, with +1 corresponding to the A of the
translation initiation codon ATG in the cDNA nomencla-
ture, according to the Human Genome Variation Society
(HGVS) nomenclature guidelines.
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DNA constructs, cell culture and luciferase assays
The coding sequences corresponding to human PITX3
wild-type, the previously reported PITX3 p.(Gly220-
Profs*95) mutant [28] and the novel PITX3 p.(Ser192A-
lafs*117) mutant were cloned into the modified pcDNA3.1
expression vector (Invitrogen, Carlsbad, CA); all constructs
were verified by DNA sequencing. The vector modification
included an insertion of a C-terminal FLAG-tag followed
by stop codon in frame with the PITX3 wild-type or mu-
tant sequences. The PITX3 c.573del mutation was gener-
ated by QuickChange Lightning Site-Directed Mutagenesis
kit (Stratagene, La Jolla, CA) according to the manufac-
turer’s protocol.
Human lens epithelial cells (B3) (ATCC, Manassas, VA)
were cultured in DMEM medium supplemented with 20%
fetal calf serum (FBS), glutamine, sodium pyruvate (1 mM)
and non-essential amino acids. The luciferase assays were
performed with two different luciferase reporter vectors,
bcd-TK-luc [28] and MIP656-bcd1,2-pGL3 [29] and as pre-
viously described. The experiments were performed two
times in triplicate for both reporters. Student’s paired t-test
with a one-tailed distribution was utilized to determine the
statistical significance of any differences in activity level.
Immunocytochemistry
B3 cells were cultured on coverslips to 50 to 80% con-
fluency, fixed with 4% formaldehyde in PBS and then
permeabilized with 0.25% Triton X-100. Indirect immuno-
fluorescent staining was performed with monoclonal anti-
FLAG M2 antibody (Sigma, St. Louis, MO) and Alexa
Fluor 568 donkey anti-mouse IgG (Invitrogen) as a sec-
ondary antibody. Hoechst 33342 (Invitrogen) was used as
a nuclear counterstain.
Electrophoretic mobility shift assay (EMSA)
Nuclear extracts were prepared from B3 cells transiently
transfected with the corresponding plasmids using the
CelLytic NuCLEAR extraction kit (Sigma) as previously
described [29]. In short, cells were harvested 48 hours
after transfection and the cellular pellet was resus-
pended in hypotonic lysis buffer with protease inhibitor
cocktail (Sigma). Igepal CA-630 was added after 15 mi-
nutes of incubation on ice, and then the cells were vor-
texed and spun down. Nuclear proteins were released
by incubation of the crude nuclear pellet in the high-salt
extraction buffer in the presence of protease inhibitors
for 30 minutes on ice followed by centrifugation. Equal
concentration of recombinant proteins was verified by
Western blot densitometry (ImageJ, NIH, Bethesda,
MD). Oligonucleotide, 5′GATCCTAATCCCGTCGCGT
CGTAATCCGGATC3′, containing two bicoid sites sep-
arated by 10 nucleotides (Bcd probe) was used in this
study [28]. For oligonucleotide labeling and detection,Biotin 3′ End DNA Labeling Kit (Pierce, Rockford, IL)
and LightShift Chemiluminescent EMSA Kit (Pierce)
were used in accordance with the manufacturer’s proto-
col. 20 fmol of biotin end-labeled probe were mixed
with binding buffer containing 50 ng/μl of Poly(dI-dC)
and 2 μl of nuclear extracts. After 20 minutes of incuba-
tion at room temperature, reactions were either diluted
with 5× Loading buffer or further incubated for 30 mi-
nutes in presence of 1 μg of goat polyclonal Pitx3 N-20
antibody (Santa Cruz Biotechnology, Dallas, TX) for the
Supershift assay. Binding reactions and free probe were
run on 5% native polyacrylamide gel in 0.5× TBE buffer.
Western blot
For Western blot, equal volumes of whole cell extract
from transfected cells were electrophoresed into 10%
SDS-polyacrylamide gel, transferred to polyvinylidine
difluoride filters (Millipore, Billerica, MA) and probed
with FLAG-M2 antibodies. After reaction with a second-
ary antibody conjugated with HRP, signal was detected
with ECL Western Blotting Substrate (GE Healthcare,
Little Chalfont, UK).
Results
PITX3 mutations and associated phenotypes
Recurrent PITX3 mutation
In the index patients of four Belgian families, the recurrent
duplication of 17-bp, c.640_656dup was found (Figure 1).
This duplication creates a frameshift mutation, p.(Gly220-
Profs*95), leading to the replacement of the normal 82 C-
terminal amino acids with 94 erroneous residues (Figure 2).
Targeted mutation analysis in available family members
demonstrated co-segregation of this mutation with disease
(Figure 3).
The first Belgian family is a three-generation family
with four affected individuals diagnosed with posterior
subcapsular cataract (PSC) (Figure 3A). The recurrent du-
plication was found in the index patient (III:1), her brother
(III:2) and her father (I:1).
The index patient (III:1) was born with severe corneal
clouding in the right eye for which rotational corneal
autografting was performed to obtain a clear optical axis,
however this eye remained without functional visual acu-
ity (VA). When she was 13 years old, she underwent lens
extraction with lens implant of her left eye. Later on, she
developed severe corneal endothelial cell loss in this eye
and therefore underwent corneal transplant at the age of
15. A follow-up ophthalmological examination at the age
of 26 revealed a VA for her right and left eye of light per-
ception and 0.1, respectively, and corneal clouding with
significant corneal endothelial loss. Her brother (III:2) also
had congenital cataract with ASD. He was pseudophakic
with a significant loss of endothelial cells. VA for his right
and left eye was 0.5 and 0.6, respectively. Their father
Figure 1 Sequence electropherograms of the identified PITX3 mutations. A. Sequence electropherograms of the four index patients with
the recurrent c.640_656dup PITX3 mutation. B. Sequence electropherogram of the proband with the novel PITX3 mutation, c.573del. The
reference sequence is displayed in blue on the top of each panel. Sequence electropherograms of the wild-type are shown at the bottom of each
panel. The mutations are indicated with a red box.
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went cataract extraction at the age of 18. No other corneal
or anterior segment anomalies were observed in him
(Figure 4). All affected individuals (III:1, III:2 and II:2)
have normal intraocular pressure (IOP).
In the second Belgian family there are three genera-
tions of affected individuals with ADCC (Figure 3B).
The recurrent mutation c.640_656dup was found in the
index case III:1; no DNA from other family members
was available for targeted mutation testing. The cata-
racts of the index patient (III:1), her father (II:7), threepaternal uncles (II:2, II:3, and II:4), and her paternal
grandmother (I:2) developed gradually during childhood
and became clinically apparent at different ages necessi-
tating cataract extractions. Bilateral cataract extraction
was performed in the index patient (III:1) at the age of 7
resulting in a bilateral best corrected visual acuity (BCVA)
of 0.2. Apart from the cataract, the index patient has
microcornea (bilateral corneal diameters of 9 mm; micro-
cornea is defined as a corneal diameter < 10 mm [30]),
corneal opacities, iridocorneal adhesions, glaucoma and
nystagmus (Figure 4). Over a period of three years she was
Figure 2 Schematic representation of mutated PITX3 proteins.
The top diagram represents the wild-type PITX3 protein. The green
box represents the homeodomain of 60 amino acids and the blue
box the OAR (named after otp, aristaless and rax) domain of 14
amino acids. The middle and bottom diagram represent the mutant
PITX3 proteins p.(Gly220Profs*95) (recurrent) and p.(Ser192Alafs*117)
(novel), respectively. The positions of the mutations are indicated
with a red line and the resulting aberrant protein segments are
highlighted by a red box.
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addition, the index patient has intellectual disability. But
as her mother and one maternal uncle (II:11) also display
intellectual disability, this was felt to be unrelated to the
paternally inherited PITX3mutation.
The third Belgian family is a four-generation PSC fam-
ily with nine affected individuals (Figure 3C). The recur-
rent duplication was found in the index patient (IV:2)
and his mother (III:3). The index patient was diagnosed
with bilateral congenital cataract and ASD. As severeFigure 3 Pedigrees of Families 1 (A), 2 (B), 3 (C), 4 (D) and 5 (E). Affect
arrow. In the genotype M stands for the mutant allele (c.640_656dup in Facentral corneal clouding was present in his right eye, he
underwent optical iridectomy however this eye remained
amblyopic. Cataract extraction of his left eye was per-
formed at the age of 8. After the extraction, the patient’s
VA improved from 0.4 to 0.7 for his left eye while the
VA for his right eye was light perception (Figure 4). His
mother (III:3) presented only with bilateral congenital
cataracts that were extracted at the age of 6. Her affected
brothers (III:4 and III:5) and mother (II:2) underwent cata-
ract extraction at the age of 17, 10 and 7 respectively.
The fourth Belgian family encompasses three genera-
tions of affected individuals with ADCC (Figure 3D). The
recurrent duplication was found in the index case III:1; no
DNA from other family members was available for tar-
geted mutation testing. The index patient (III:1) is 3.5 years
old and presented with nystagmus (manifesting latent left
eye), corneal haze and iridocorneal adhesions with endo-
thelial loss. The developmental anomaly was more severe
in the right eye. VA for her right and left eye is light
perception and 0.4, respectively. Her IOP was 12 mmHg
(Figure 4). Her father (II:6) only presented with congenital
cataract that was extracted at the age of 12.
Novel PITX3 mutation
In a Belgo-Romanian family with ADCC a novel 1-bp de-
letion c.573del was found in exon 4, p.(Ser192Alafs*117),ed individuals are indicated by filled symbols and index patients by an
milies 1–4 and c.573del in Family 5) and + for the wild-type allele.
Figure 4 Clinical pictures. In this figure, anterior segment pictures are presented for both right (RE) and left eyes (LE). All eyes shown are
pseudophakic, except for family 4 (panel D). A. Both eyes of the father (Family 1, II:1) show corneas with small diameter (10 mm) and normal
transparency. An anterior chamber lens implant is observed with iris atrophy and iatrogenic correctopia. The index patient (III:1) underwent a
rotational corneal autograft in the RE. Corneal clouding, iridocorneal adhesions and iris atrophy can be seen in the LE. Both eyes of the brother
(III:2) show inferior corneal clouding with endothelial haze. B. In both eyes of the index patient (Family 2, III:1) corneal opacities can be observed.
C. In the RE of the index patient (Family 3, IV:2) optical iridectomy was performed because of severe central corneal clouding. In the LE
corectopia and corneal haze is observed. D. Iridocorneal adhesions and iris hypoplasia are observed in both eyes of the index patient (Family 4,
III:1) although more pronounced in the RE. E. In the index patient (Family 5, III:1) and her brother (III:2) microcornea (6 mm) and severe corneal
opacities are observed.
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identified this 1 bp-deletion in her father (II:2) as well; no
DNA samples were available from other family members
(Figure 3E). This 1-bp deletion creates a frameshift start-
ing at codon 192 and introduces 116 novel residues before
resulting in a stop codon downstream of the original stop
codon (Figure 2). The index patient (III:1) was diagnosed
with congenital cataract for which she underwent cataract
extraction when she was 1 year old. Follow-up ophthal-
mological examination at the age of 25 demonstrated a
VA for her right and left eye of light perception and 0.02,
respectively, bilateral microcornea (6 mm), corneal opaci-
ties and iridocorneal adhesions. She underwent optical iri-
dectomy of both eyes. Her IOP was normal. Her brother(III:2) has microcornea (5 mm) and corneal opacities in
addition to congenital cataract (Figure 4). Their father
(II:2) has microcornea and congenital cataract.
Functional characterization of novel PITX3 mutation
p.(Ser192Alafs*117) compared to the recurrent mutation
p.(Gly220Profs*95)
Subcellular localization
Consistent with its role as a transcription factor, PITX3
was found to localize to the nucleus [28]. The novel
PITX3 mutant p.(Ser192Alafs*117) displayed a similar
nuclear localization as observed for the wild-type PITX3
and the previously reported recurrent mutant p.(Gly220-
Profs*95) (Figure 5A).
Figure 5 Subcellular localization (A), DNA-binding (B) and transactivation activity (C) of the novel PITX3 mutation in comparison with
the recurrent mutation. A. Immunocytochemistry of the PITX3 wild-type and mutant proteins transfected in B3 lens epithelial cells. Cells were
stained with monoclonal anti-FLAG M2 primary antibody and Alexa Fluor 568 donkey anti-mouse IgG as a secondary antibody (red); Hoechst
33342 was used as a nuclear counterstain (blue). All three proteins localize predominantly to the nucleus. B. Results of EMSA experiments
demonstrating the DNA-binding capacity of the PITX3 wild-type and mutant proteins. The profile of the wild-type PITX3 protein (third from the
left) displays two major bands likely representing DNA interactions with PITX3 homo- or hetero-dimers (upper band; arrow) or PITX3 monomers
(lower band; dashed arrow). The profile of the mutant PITX3 proteins only shows the lower band. Addition of anti-PITX3 antibody results in the
appearance of a supershifted band (asterisk) and disappearance of the other bands. Western blot (bottom) shows similar levels of PITX3 wild-type
and mutant proteins in the nuclear extracts used for EMSA experiments. C. Luciferase assay results for wild-type and mutant PITX3 co-transfected
with the bcd-TK-luc or MIP656-bcd1,2-pGL3 reporters in human lens epithelial cells. The values are reported as fold changes of luciferase activity in
comparison to an empty vector (pcDNA3.1). All luciferase activities were normalized to β-galactosidase activity and error bars indicate the
standard deviation of two independent experiments performed in triplicate. The asterisk indicates the statistically significant differences in fold
change (p < 0.001).
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It has been previously shown that PITX3 mutations result
in decreased DNA-binding activities [28]. To assess if the
novel p.(Ser192Alafs*117) mutation has a similar effect on
DNA-binding activity, we performed EMSA for the novel
mutant in comparison to the previously reported recur-
rent p.(Gly220Profs*95) mutant and wild-type proteins.
The results were also compared to the EMSA profiles of
the bcd probe alone and with mock nuclear extracts (NE)
to exclude nonspecific binding activity. The observed pro-
file for the wild-type protein consisted of two major bands
in agreement with previously reported results (Figure 5B).
The fast-migrating band probably corresponds to PITX3
binding DNA as a monomer and the slower migrating
bands may represent PITX3 homodimer- or PITX3
heterodimer-DNA complexes with other proteins [13,28].
The slower migrating bands have disappeared in the
EMSA profiles of both PITX3 mutants while the fast-
migrating band, likely representing monomeric DNA-
binding activity, remained. The specificity of the assay
was verified by adding an anti-PITX3 antibody resulting
in a supershifted band and fading of the other bands
(Figure 5B). Western blot analyses were performed to
confirm the equal presence of wild-type and mutant
PITX3 protein in the nuclear extract used for the EMSA
experiments (Figure 5B).
Transactivation activity
In addition to altered DNA-binding properties, it has also
been shown that PITX3 mutants exhibit a reduced trans-
activation activity [28]. Using luciferase assays in human
lens epithelial cells we evaluated the transactivation activ-
ity of the novel PITX3 mutant p.(Ser192Alafs*117) in
comparison to the recurrent p.(Gly220Profs*95) mutant
and wild-type proteins (Figure 5C). Co-transfection of the
wild-type PITX3 with the bcd-TK-luc reporter resulted in
a ~10-fold increase in luciferase activity in comparison
with an empty pcDNA3.1 vector, while the novel p.
(Ser192Alafs*117) and recurrent p.(Gly220Profs*95) mu-
tants resulted in a ~1.7-fold (16.8% of wild-type activity;
p < 0.001) and ~3.2 fold increase (31.5% of wild-type activ-
ity; p < 0.001), respectively. A similar trend could be
observed using the MIP656-bcd1,2-luc reporter, as a ~13-
fold increase in luciferase activity was detected when this
reporter was co-transfected with wild-type PITX3. In
contrast, the luciferase activity for the novel and recur-
rent PITX3 mutants was found to be 39.2% and 43.4%
(p < 0.001) of wild-type activity, respectively.
Discussion
Congenital cataract is a clinically and genetically heteroge-
neous condition. Most genes are associated with isolated
congenital cataracts while mutations in the transcription
factor genes PAX6, FOXE3, EYA1, MAF, and PITX3 lead tocongenital cataract with ASD [3-7]. Of particular note,
PITX3 mutations can cause isolated congenital cataract as
well as ASD-associated cataract, even within the same fam-
ily [7]. This inter- and intrafamilial phenotypic variability
can likely be ascribed to modifier genes or environmental
factors. PITX3 mutations represent a rare cause of congeni-
tal cataract with or without ASD. Indeed, only five unique
PITX3 mutations in 13 different families were known be-
fore the onset of this study (Table 1). The most common
mutation is the 17-bp duplication c.640_656dup accounting
for more than half of the families [7,18-21,23,24] and
ADCC with ASD has been documented only in association
with this duplication. Notably, the novel PITX3 mutation
c.573del, p.(Ser192Alafs*117), was found in a family with
ADCC and ASD, thus being the second mutation leading
to this phenotype. Like the other reported PITX3 muta-
tions, this novel frameshift mutation is located outside the
homeodomain. Interestingly, all PITX3 frameshift mutants
lack the C-terminal 14-amino-acid motif (see Additional
file 2), which is conserved in numerous paired-like homeo-
domain proteins and is named the OAR domain, after the
homeodomain genes otp, aristaless, and rax [14]. The
function of this OAR domain is not fully established yet
but it has been suggested that it could interact with
additional proteins, hence mediating the target specifi-
city of the homeobox-containing transcription factors
[13,14]. Although the OAR domain is conserved in all
of these homeodomain proteins, its function appears to
vary among the proteins. Functional assays with different
deletion mutants of Otp showed that mutants missing the
region downstream of the homeodomain, including the
OAR domain, presented with a different DNA-binding
profile and a substantial reduction of transactivation activ-
ity, thus suggesting an activating regulatory role [31]. The
OAR domain is also important for the transactivation ac-
tivity of SHOX as a truncated SHOX mutant lacking this
domain has an abolished transactivation activity [32]. In
contrast, a study of the Pitx2 C-terminus demonstrates an
inhibitory role for the OAR domain as it was shown that
the presence of this domain inhibits DNA-binding while
masking this domain through protein interaction stimu-
lates DNA-binding and transcriptional activation [33].
This finding was supported by studies in Prx2 and Cart1
where the OAR domain inhibits transactivation and serves
as an intramolecular switch of its transactivation activity,
respectively [34,35]. To explore the function of the C-
terminal region in PITX3, Sakazume et al. investigated the
effect of PITX3 mutants on DNA-binding and transactiva-
tion activity. In accordance with the Otp and SHOX study,
an altered DNA-binding profile and diminished transcrip-
tional activity was shown [28].
Both the novel and recurrent PITX3 mutations found
here disrupt the C-terminus including the OAR domain.
As they both lead to a similar phenotype, we assessed
Table 1 Overview of the different PITX3 mutations described in human and associated phenotypic details
Mutation Mode of inheritance Clinical features Reference
c.38G > A, p.(Ser13Asn) Dominant Mother and son with ADCC and glaucoma at a
later age.
7
c.542del, p.(Pro181Leufs*128) Dominant Four-generation English family with isolated PPC. 26
c.573del, p.(Ser192Alafs*117) Dominant Belgo-Romanian family with ADCC. Two individuals
also have ASD.
This study, Family 5
c.640_656dup, p.(Gly220Profs*95) Dominant Six-generation family with ADCC and ASD. 7
Four-generation English family with PPC. One
individual also has ASD and congenital glaucoma.
18, 19
Four-generation English family with PPC. Four
individuals also have ASD.
18, 19
Five-generation English family with isolated PPC. 18, 19
Four-generation Chinese family with isolated PPC. 18
Four-generation British/German family with isolated
PPC.
20
Five-generation English family with isolated PPC. 21
Four-generation Australian family with PSC. Seven
individuals also have ASD.
23, 24
Three-generation Belgian family with PSC. Two
individuals also have ASD.
This study, Family 1
Three-generation Belgian family with ADCC. One
individual also has ASD.
This study, Family 2
Four-generation Belgian family with PSC. One
individual also has ASD.
This study, Family 3
Three-generation Belgian family with ADCC. One
individual also has ASD.
This study, Family 4
c.640_656del, p.(Ala214Argfs*42) Recessive Daughter from healthy first cousin parents with
ASD and severe congenital microphthalmia.
25
c.650del, p.(Gly217Alafs*92) Dominant Four-generation Hispanic family with isolated
cataract.
18
Dominant/recessive Three-generation Lebanese family with PPC. Two
brothers from a consanguineous mating showed a
more severe ocular and neurologic phenotype in
addition to PPC.
22
Microdeletion of 10q24.32
encompassing PITX3
De novo Patient with Smith–Magenis syndrome-like behav-
ioural abnormalities, intellectual disability and dys-
morphic features but no eye phenotype.
41
Mutation nomenclature is based on reference transcript NM_005029.3 and the HGVS guidelines.
ADCC: autosomal dominant congenital cataract; PPC: posterior polar cataract; ASD: anterior segment dysgenesis; PSC: posterior subcapsular cataract.
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functional assays. Since all PITX3 frameshift mutations
utilize a stop codon located downstream of the normal
stop codon in the last coding exon, they are not predicted
to be subject to nonsense mediated decay (NMD). The
novel PITX3 mutant retained its nuclear localization but
displayed altered DNA-binding properties similar to the
recurrent PITX3 p.(Gly220Profs*95) mutant. In addition,
a similar decrease of transcriptional activity compared to
wild-type PITX3 was observed for the novel and recurrent
PITX3 mutants. These mutations may produce aberrant
protein that can either antagonize DNA-binding activity
of wild-type proteins or form inactive dimers with wild-type proteins, impairing wild-type protein function in
both situations. Co-transfection assays with mutant and
wild-type PITX3 could not, however, substantiate a
dominant-negative effect [28]. A loss-of-function effect
for the PITX3 mutations is therefore more probable.
This view is supported by the report on a large ADCC
pedigree in which two brothers from a consanguineous
mating are homozygous for the PITX3 mutation segre-
gating in the family and manifest a more severe ocular
and neurological phenotype, with severe microphthalmia
and neurological involvement in addition to cataract [22].
This severe combination of ocular and neurological in-
volvement has also been described in the two spontaneous
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estingly, besides its expression in the developing lens,
Pitx3 expression was also observed in the dopamine neu-
rons of the midbrain [10]. A severe loss of dopaminergic
neurons in the substantia nigra was also observed in
aphakia and eyeless mice. As these neurons play import-
ant roles in the control of movement, emotion, cognition,
and reward related behavior, this neuronal loss can explain
the observed locomotor and behavioural defects [36-39].
Unlike the human PITX3 mutations, heterozygous Pitx3
mice were phenotypically normal which might be attrib-
uted to interspecies differences, as mice seem to be less
sensitive to gene dosage. However, the loss-of-function
hypothesis is challenged by the report on another con-
sanguineous mating between phenotypically normal first
cousins resulted in a girl homozygous for the PITX3 mu-
tation c.640_656del, manifesting as severe bilateral micro-
phthalmia and ASD but without cataract or a neurological
phenotype [25]. This phenotype is reminiscent of the
manifestations in the Texel Sheep as this breed displays
microphthalmia as an autosomal recessive congenital con-
dition, caused by a missense mutation in the conserved
homeodomain of PITX3, c.338G > C, p.(Arg113Pro) [40].
In addition, a heterozygous microdeletion of 10q24.32
encompassing PITX3 in a patient with Smith–Magenis
syndrome-like behavioral abnormalities was recently de-
scribed. The patient also presented with intellectual dis-
ability and dysmorphic features but, surprisingly, lacked
an eye phenotype. Analysis of neurotransmitters in his
cerebrospinal fluid revealed an absence of L-DOPA and L-
DOPA treatment led to mild improvement of his behavior
[41]. Based on these observations and the selective loss of
dopaminergic neurons in the Pitx3 mutant mice, it might
be interesting to assess the dopaminergic function of pa-
tients with PITX3 mutations.
Taken together, these findings suggest that PITX3 asso-
ciated phenotypes most likely result from a more complex
mutational mechanisms than loss of function effects alone
and that more extensive studies are needed to correlate
the phenotypic and molecular consequences of PITX3
mutations.
Conclusions
In this study, we identified a novel PITX3 mutation, p.
(Ser192Alafs*117) and the recurrent p.(Gly220Profs*95)
mutation in one Belgo-Romanian family and four Belgian
families with ADCC and ASD, respectively. The novel
mutation p.(Ser192Alafs*117) is only the second PITX3
mutation to be associated with this combined phenotype,
along with the recurrent mutation p.(Gly220Profs*95).
The similarity in phenotypic expression could be ex-
plained by in vitro functional studies which demonstrated
similar molecular consequences for the novel p.(Ser192A-
lafs*117) and the recurrent p.(Gly220Profs*95) mutations.Additional files
Additional file 1: PCR primers and conditions for molecular
screening of PITX3.
Additional file 2: Schematic representation of all reported mutated
PITX3 proteins. The top diagram represents the wild-type PITX3 protein.
The green box displays the homeodomain of 60 amino acids and the
OAR (named after otp, aristaless and rax) domain of 14 amino acids is
displayed by a blue box. The recurrent p.(Gly220Profs*95) and novel
p.(Ser192Alafs*117) mutations are indicated in bold. The positions of
the mutations are indicated with a red line and a red box displays the
resulting aberrant protein segments.
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